EPCAM and carcinoma: Antagonizing antibodies such as EpAb2-6 and small molecule inhibitors that compete with EpCAM RIP or with EpICD functions could develop into promising candidate drugs for the treatment of EpCAM-positive carcinomas and the formation of lethal metastases.